An interventional study of Home-based training and Center-based training in Hematologic Malignancy and Lymphoma, sponsored by Brno University Hospital. Completed at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Brno University Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hematologic Neoplasms with a site in Czechia — 7 open to participants now, 8 under way, 3 of them phase 3. Hematologic Neoplasms · Czechia.
Among the 15 studies in Hematologic Neoplasms with a site in Czechia, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is the only one with no phase, and was the 12th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →7 of the 15 studies in Hematologic Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:
CSL Behring · Sites in Czechia, United States, Belgium and 8 more countries
Ages 18+
Kura Oncology, Inc. · Sites in Czechia, United States, Australia and 14 more countries
Ages 18+
JaxBio Ltd · Sites in Czechia, Greece, Israel and 1 more country
Ages 18+ · Healthy volunteers
Miltenyi Biomedicine GmbH · Sites in Czechia, Austria, Belgium and 11 more countries
Ages 18–70
Merck Sharp & Dohme LLC · Sites in Czechia, United States, Argentina and 19 more countries
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7
First in 2007; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 183 across the 14 interventional studies, 3,000 across the 1 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 10 most frequent:
Brno University Hospital is the lead sponsor of 91 studies on the registry; 22 are open to participants now.
Brno University Hospital has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Hematologic Neoplasms with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735704JaxBio LtdEarly Detection and Screening of Hematological Malignancies - SANGUINE | 2027-01-31 |
| NCT03328078Curis, Inc.CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Hematologic Neoplasms with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates whether the 12-week home-based exercise training with remote guidance and telemonitoring compared to regular center-based training leads to better long-term cardiorespiratory fitness and physical activity levels in post-treatment patients with lymphoma.
80 lymphoma cancer patients post-treatment (except adjuvant treatment) will be enrolled in the study. Cardiorespiratory fitness (peak oxygen consumption), adverse events, body composition, quality of life, costs and adherence to exercise prescription will be evaluated at baseline, 12-week, and year after enrollment.
Investigators assume that home-based training with remote guidance and telemonitoring with objective training data obtained during rehabilitation after cancer treatment will improve long-term motivation and effectiveness of independent training in cancer survivors, resulting in superior cardiorespiratory fitness and physical activity levels.
Inclusion Criteria: Participants
Exclusion Criteria: Participants
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 weeks of home-based exercise training using modern technology to transfer exercise data remotely. The participants receive a heart rate monitor and sensor. Three sessions per week will be performed (36 sessions overall).
Device: Home-based training
12 weeks of centre-based exercise training under supervision physiotherapists specializing in exercise rehabilitation. The participants receive a heart rate monitor and sensor. The patients in the Center-based training group receive an individually tailored training program on a treadmill and a bicycle ergometer. Three sessions per week will be performed (36 sessions overall).
Device: Center-based training
Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
Cardiorespiratory fitness
Peak oxygen uptake during cardiopulmonary exercise test
Time frame: Change from baseline to 12 weeks and 52 weeks
Health-related quality of life
Health-related quality of life (SF-36 Form) yields a score for each domain of health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state
Time frame: Change from baseline to 12 weeks and 52 weeks
Satisfaction - self-completed questionnaire
Subjects will be provided with a 5-item self-completed questionnaire developed by our research team that will measure their satisfaction with the intervention they received and the study in general. The items will be presented in the form of statements to which subjects will be asked to respond using a 1-5 Likert scale ("strongly agree", "agree", "not sure", "disagree", and strongly disagree").
Time frame: 12 weeks and 52 weeks
Body water
Total body water in liters will be measured by bioelectrical impedance analysis.
Time frame: Change from baseline to 12 weeks and 52 weeks
Muscle mass
Total muscle mass in kilograms will be measured by bioelectrical impedance analysis.
Time frame: Change from baseline to 12 weeks and 52 weeks
Body fat percentage
Body fat percentage will be measured by bioelectrical impedance analysis.
Time frame: Change from baseline to 12 weeks and 52 weeks
Incidence of exercise adverse events assessed by 5 grade scale
Participants will be encouraged to use the contact details for reporting incidence of exercise adverse events at any time throughout the study period. The type, incidence, and severity of adverse events by scale (Grade 1: Mild, asymptomatic or mild symptoms; Grade 2: Moderate, minimal; Grade 3: Severe or medically significant; Grade 4: Life-threatening consequences; and Grade 5: Death) will be noted.
Time frame: Data will be recorded continuously from the intervention's baseline for 12 weeks and then for 52 weeks
Training adherence (Number of compliant participants)
Evaluation of the total number of compliant participants (The criterium of compliance with the rehabilitation program is set at 70% of the prescribed training lessons, 100% = 36 lessons)
Time frame: 12 weeks
Maximum Grip Strength
Maximum grip strength during dynamometer evaluation
Time frame: Change from baseline to 12 weeks and 52 weeks
Ran from Apr 2023 to primary completion in Sep 2026, 41 months.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's 41 months is close to that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2025 → Sep 2026 and completion Dec 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brno University Hospital